Trials / Active Not Recruiting
Active Not RecruitingNCT05319431
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
An Open Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of AK104 Plus Lenvatinib and TACE in the Treatment of Unresectable, Non-metastatic Hepatocellular Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK104 | Subjects will receive AK104 until disease progression or for a maximum of 24 months |
| DRUG | Lenvatinib | Subjects will receive lenvatinib until disease progression or for a maximum of 24 months |
| PROCEDURE | TACE | On demand TACE |
Timeline
- Start date
- 2022-06-28
- Primary completion
- 2023-08-15
- Completion
- 2025-06-30
- First posted
- 2022-04-08
- Last updated
- 2025-03-12
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05319431. Inclusion in this directory is not an endorsement.